Stock & Company Details
Rhythm Pharmaceuticals Inc. $RYTM
Price:
N/A
N/A
69M
$6.2B
52 Week High:
N/A
10 Day Average Volume:
N/A
-29.43
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
RYTM technical indicators
Latest Rhythm Pharmaceuticals Inc. (RYTM) indicator readings as of 2026-10-09.
RYTM's 14-day RSI is 32.0, in neutral territory. At $90.78 it is trading 7.7% below its 200-day moving average of $98.34, and below its 50-day average of $103.88. Price sits near the lower Bollinger Band ($88.25 to $103.26). ADX reads 36.7, indicating a trending market.
RYTM backtested strategy results
How 4 rule-based strategies performed on Rhythm Pharmaceuticals Inc. (RYTM) over recent history, last backtested 2026-09-08. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | -11.3% | 15% | 13 | -71.0% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | +267.3% | 31% | 29 | -54.1% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | +57.5% | 30% | 37 | -57.6% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | +130.1% | 55% | 33 | -64.8% |
Overview
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies.
Finance Bot
Ask your questions
Start by typing a question below.
